Supernus Pharmaceuticals Inc - Asset Resilience Ratio
Supernus Pharmaceuticals Inc (SUPN) has an Asset Resilience Ratio of 13.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Supernus Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Supernus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Supernus Pharmaceuticals Inc (SUPN) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Supernus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SUPN company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $199.37 Million | 13.29% |
| Total Liquid Assets | $199.37 Million | 13.29% |
Asset Resilience Insights
- Moderate Liquidity: Supernus Pharmaceuticals Inc has 13.29% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Supernus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Supernus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Cipla Limited
NSE:CIPLA |
Drug Manufacturers - Specialty & Generic | 20.75% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.92% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 11.00% |
Annual Asset Resilience Ratio for Supernus Pharmaceuticals Inc (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Supernus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.41% | $180.22 Million | $1.45 Billion | -15.68pp |
| 2024-12-31 | 28.09% | $384.28 Million | $1.37 Billion | +14.02pp |
| 2023-12-31 | 14.07% | $179.82 Million | $1.28 Billion | -7.55pp |
| 2022-12-31 | 21.63% | $368.21 Million | $1.70 Billion | +13.56pp |
| 2021-12-31 | 8.07% | $136.25 Million | $1.69 Billion | -0.84pp |
| 2020-12-31 | 8.90% | $133.89 Million | $1.50 Billion | -5.38pp |
| 2019-12-31 | 14.28% | $165.69 Million | $1.16 Billion | -2.47pp |
| 2018-12-31 | 16.75% | $163.77 Million | $977.81 Million | +7.39pp |
| 2017-12-31 | 9.36% | $39.74 Million | $424.46 Million | +1.70pp |
| 2016-12-31 | 7.66% | $23.72 Million | $309.57 Million | -7.19pp |
| 2015-12-31 | 14.86% | $28.04 Million | $188.73 Million | -12.73pp |
| 2014-12-31 | 27.59% | $37.94 Million | $137.51 Million | -16.75pp |
| 2013-12-31 | 44.34% | $49.21 Million | $111.00 Million | -6.95pp |
| 2012-12-31 | 51.29% | $48.21 Million | $93.99 Million | +50.83pp |
| 2011-12-31 | 0.46% | $245.00K | $53.73 Million | -18.61pp |
| 2010-12-31 | 19.07% | $8.96 Million | $47.01 Million | -24.88pp |
| 2009-12-31 | 43.95% | $35.12 Million | $79.90 Million | +34.23pp |
| 2008-12-31 | 9.73% | $7.50 Million | $77.13 Million | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more